PVD Management in a post-COMPASS World

A subanalysis of the COMPASS trial found that combination treatment with rivaroxaban and aspirin reduced incidence of major adverse limb events by 43%.

Source: ConsultantLive - October 11, 2018 Category: Internal Medicine Authors: Gregory W. Rutecki, MD Tags: Cardiovascular Disease Source Type: news